About Kogenate® FS [Antihemophilic Factor (Recombinant)]
Hemophilia A affects as many as 400,000 people around the world. In the early 1970s, we introduced our first factor VIII (FVIII) product for patients with hemophilia A.
Today, we are proud to make available our recombinant factor VIII treatment: Kogenate® FS.* Kogenate® FS is indicated for the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor FVIII. Kogenate® FS provides a means of temporarily replacing the missing clotting factor in order to correct or prevent bleeding episodes, or in order to perform emergency surgery or elective surgery in people living with hemophilia.
We manufacture Kogenate® FS at our Berkeley site, and ship it around the world.
Every Step of the Way: Kogenate® Manufacturing Video
If your firewall blocks video sharing sites, you will be unable to watch this video.
* Kogenate® FS Antihemophilic Factor (Recombinant), is a recombinant Factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. For important safety and use information, please see the full prescribing information.
* Product information is intended for U.S. Audiences Only
